Daiwa Securities Group Inc. Makes New Investment in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Daiwa Securities Group Inc. bought a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 4th quarter, Holdings Channel reports. The institutional investor bought 1,515 shares of the medical equipment provider’s stock, valued at approximately $136,000.

Several other hedge funds have also recently bought and sold shares of LNTH. Wilmington Savings Fund Society FSB bought a new position in shares of Lantheus during the 3rd quarter worth approximately $25,000. Kestra Investment Management LLC bought a new position in shares of Lantheus during the 4th quarter worth approximately $27,000. UMB Bank n.a. grew its stake in shares of Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after acquiring an additional 134 shares in the last quarter. RiverPark Advisors LLC bought a new position in shares of Lantheus during the 3rd quarter worth approximately $74,000. Finally, Parkside Financial Bank & Trust grew its stake in shares of Lantheus by 49.4% during the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider’s stock worth $76,000 after acquiring an additional 280 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares of the company’s stock, valued at approximately $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now directly owns 33,207 shares of the company’s stock, valued at $3,146,695.32. This represents a 2.92 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.50% of the company’s stock.

Lantheus Trading Up 1.8 %

NASDAQ:LNTH opened at $101.10 on Monday. The firm has a fifty day simple moving average of $92.07 and a 200 day simple moving average of $96.68. Lantheus Holdings, Inc. has a 1-year low of $56.44 and a 1-year high of $126.89. The stock has a market capitalization of $6.92 billion, a PE ratio of 16.82 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The company had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. On average, equities analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on LNTH shares. Truist Financial raised their price target on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. The Goldman Sachs Group initiated coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price for the company. Finally, JMP Securities reissued a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, Lantheus has an average rating of “Moderate Buy” and an average price target of $132.86.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.